Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (39058)	5/10/1999 2:49:00 PM
From: Wendy Russell	Respond to of 120523

Block volume is 56K, in four trades. Non block volume is 1.18M in 1369 trades, as of 11:45 PST

To: debra vogt who wrote (39058)	5/10/1999 2:52:00 PM
From: lee kramer	Read Replies (1) \| Respond to of 120523

DEBRA...and we missed you too. Re: the size of the trades...does it matter? A stock that trades 200,000k avg. volume suddenly trades 1,000,000. That may not say enough, but it still says plenty.(Lee).

To: debra vogt who wrote (39058)	5/10/1999 2:54:00 PM
From: Northern Cougar	Respond to of 120523

debra...BIOM only 4 blocks so far, total for blcks 56,000, out of 1.25 million shrs traded. There are many 1000 shrs trade going through probably because the shr price is around $5. good luck hope you got a whole a bunch at a lower price. :) N.C.

To: debra vogt who wrote (39058)	5/10/1999 2:55:00 PM
From: eyg	Respond to of 120523

debra....BIOM - mostly small trades, 1 5k trade over an hour ago and a 3k trade about half an hour ago, several 1K trades but majority below 1k, hope this helps....be happy to PM you the transaction log at end of day.

To: debra vogt who wrote (39058)	5/10/1999 8:43:00 PM
From: debra vogt	Read Replies (1) \| Respond to of 120523

Here is some info about BIOM which I mentioned earlier today, I have owned this stock for several months, I did not buy it as a trade. It has been going up the last several days on higher than normal volume. Today's volume was particularly high, may continue to run at least into the presentation this weekend 05/07/99 PRN Biomira Inc. Announces 1st Quarter Results 04/20/99 PRN Biomira Vaccine Subject of American Society of Clinical Oncology Annual Mee... More News... How Do I... Biomira Vaccine Subject of American Society of Clinical Oncology Annual Meeting Presentations Cancer Vaccine Tested in Bone Marrow Transplant and Stem Cell Rescue Patients April 20, 1999 07:58 AM EDMONTON, Alberta, April 20 /PRNewswire/ -- Biomira Inc. BIOM (Toronto, Montreal: BRA) announced today that findings from clinical trials with its lead product candidate, THERATOPE(R) vaccine, will be presented at the 35th annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, May 15-18. Leona Holmberg, M.D., Ph.D., Brenda Sandmaier, M.D., and co-investigators at the Fred Hutchinson Cancer Research Center, will be presenting data from a clinical trial of THERATOPE(R) cancer vaccine in patients with breast and ovarian cancers following hematopoietic stem cell transplant. Separately, Charles Vogel, M.D., FACP, Columbia Cancer Research Network, has been informed that an abstract concerning the use of THERATOPE(R) vaccine in Biomira's multi-center bridging study in women with metastatic breast cancer following first-line chemotherapy, was accepted for publication in the 1999 ASCO Proceedings. The bridging study was carried out before the Company initiated its pivotal Phase III trial currently underway. "We are very pleased that the efforts of our investigators using THERATOPE(R) cancer vaccine are being acknowledged by this prestigious organization," said Alex McPherson, M.D., Ph.D., President and CEO of Biomira. "We are working diligently to see this promising new drug in the fight against cancer through to commercialization." Biomira initiated pivotal Phase III clinical trials with THERATOPE(R) vaccine late last year, and plans to enroll 900 evaluable patients with metastatic breast cancer at approximately 75 sites worldwide. Earlier studies suggested clinically significant survival benefit in metastatic breast cancer patients treated with THERATOPE(R) vaccine. THERATOPE(R) vaccine consists of a synthetic antigen that mimics STn, a cancer-associated epitope, and induces the body to mount an effective immune response against cancer cells. The data being featured at the May conference further support findings that THERATOPE(R) vaccine may have potential as a powerful tool in battling cancer. ASCO's 1999 Annual Meeting will be at the Georgia World Congress Center and will feature over 150 scientific and educational presentations, as well as an exhibition with over 250 industry representatives. It is the largest professional meeting on clinical data about new cancer therapies. Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management.